SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

by Selleckchem | Aug 24 2023

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.

Comments:

Gastrointestinal stromal tumor (GIST) is indeed the most common malignant neoplasm originating from mesenchymal tissue. It has served as a model for the development of targeted therapies in cancer, demonstrating significant advancements in treatment outcomes. The introduction of tyrosine kinase inhibitors (TKIs) that target the KIT and PDGFRA proteins has revolutionized the management of both localized and advanced stages of GIST. These targeted therapies have shown remarkable efficacy, even in a disease that was previously considered resistant to systemic treatments.

In Spain, the guidelines for the diagnosis and treatment of GIST patients have been developed through a collaborative effort between the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS). These guidelines aim to provide an updated and comprehensive consensus on the management of GIST. One key recommendation highlighted in these guidelines is the importance of a multidisciplinary approach to patient care. It is strongly encouraged that GIST patients be managed by multidisciplinary teams in specialized reference centers.

The multidisciplinary approach ensures that experts from various medical disciplines, such as medical oncology, surgical oncology, radiology, and pathology, collaborate to provide the best possible care for GIST patients. This approach allows for comprehensive evaluation, accurate diagnosis, and individualized treatment planning based on the specific characteristics of each patient's tumor. By centralizing the management of GIST cases in specialized reference centers, patients can benefit from the expertise and experience of healthcare professionals who are familiar with the intricacies of this disease.

In summary, the development of targeted therapies has significantly improved the prognosis of GIST patients. The joint guidelines from SEOM and GEIS emphasize the importance of a multidisciplinary approach and the centralization of patient management in reference centers. These measures aim to ensure that GIST patients receive the highest quality of care, leading to improved outcomes and survival rates.